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Abstract 
As part of our research into the mechanisms of protein wasting and muscle weakness during critical illness, we here investigate 
various aspects of energy metabolism. Intraperitoneal injection of zymosan in rats leads to an acute phase of critical illness followed by a 
prolonged recovery phase. Previously we observed low activities of mitochondrial enzymes, reduced protein synthesis rates and low 
concentrations of glutamine in skeletal muscle of zymosan-treated rats. In the present study we investigated (1) whether decreases in high 
energy phosphates are present in skeletal muscle of these rats and (2) whether an impairment in the glycolytic pathway or the 
tricarboxylic acid cycle leads to these decreases. Concentrations of creatine phosphate and ATP were decreased in zymosan-treated rats to 
approx. 85% of pair-fed control values respectively on day 2 and on days 4 and 6 after treatment. Concentrations of tricarboxylic acid 
(TCA) cycle intermediates were decreased to 80% on day 6 after zymosan treatment. Lactate/pyruvate ratio and concentrations of lactate 
and glycogen were normal at all sampling times. We conclude that no major changes in concentrations of high energy phosphates and in 
concentrations of intermediates of TCA cycle, glycolysis and glycogenolysis were present. This indicated that, although the maximal 
oxidative capacity (mitochondrial content) is decreased, no derangement i  energy metabolism seems to be present in skeletal muscle of 
critically ill and recovering rats. 
Keywords: Zymosan; Skeletal muscle; Critical illness; Energy metabolism; High energy phosphate; Tricarboxylic acid cycle 
1. Introduction 
High energy phosphates (e.g., ATP and creatine phos- 
phate) are the direct sources of energy for the cell. De- 
creased concentrations of ATP and creatine phosphate 
have been reported in skeletal muscle of critically ill 
patients and animal models [1-6]. Both muscle contraction 
and protein synthesis require energy. A decreased avail- 
ability of high energy phosphates or a reduced capacity to 
synthesize ATP may, therefore, lead to low protein synthe- 
sis rates, loss of muscle mass and muscle weakness. All 
these features are characteristic for severe illness. Loss of 
muscle mass as a result of decreased protein synthesis 
rates occurs during the acute phase of critical illness, 
whereas muscle weakness may occur during this phase but 
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is mainly manifested uring the recovery phase. Patients 
recovering from severe illness complain of increased fati- 
gability and muscle weakness up to months after leaving 
the hospital. In the present study derangements in energy 
metabolism were, therefore, studied during both the acute 
phase and recovery in a rat model of critical illness. 
Recently we described a rat model for critical illness 
which is characterized by an acute phase of severe illness 
(2 days) followed by a prolonged recovery phase [7]. The 
illness was induced by injecting rats with zymosan, an 
extract of yeast cell wall and a potent activator of 
macrophages and complement system. A rapid fall in 
mitochondrial content of skeletal muscle was observed 
during the acute phase. This low mitochondrial content 
was maintained uring the recovery phase and still present 
6 days after treatment [8]. Most ATP is produced by 
aerobic processes located within the mitochondria. The 
tricarboxylic acid (TCA) cycle plays a vital role in these 
processes. Low concentrations of mitochondria may well 
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implicate that the concentration of TCA cycle intermedi- 
ates and mitochondrial ATP production are reduced. A low 
aerobic apacity to produce ATP may lead to an increased 
anaerobic production by enhanced glycolysis and glyco- 
genolysis. In the present study we, therefore, investigated 
(1) whether concentrations of high energy phosphates are 
decreased in skeletal muscle during the acute phase of 
critical illness and recovery from it; and (2) whether this is 
accompanied by reduced concentrations of TCA cycle 
intermediates and by increased glycolysis and glycogeno- 
lysis (decreased glycogen and increased lactate concentra- 
tions). 
Newsholme and colleagues [9] hypothesized that carbon 
skeletons obtained via the 'first-half' of the TCA cycle in 
part are used to synthesize glutamine via 2-oxoglutarate 
and glutamate. This glutamine may subsequently be re- 
leased by muscle and used by lymphocytes and 
macrophages. A decreased availability of TCA cycle inter- 
mediates could, therefore, in addition to a deranged energy 
supply, lead to an impaired glutamine production by skele- 
tal muscle and subsequently an impaired function of the 
immune system. Decreased concentrations of glutamine in 
skeletal muscle are a commonly observed feature during 
severe illness, and were also observed in the zymosan- 
treated rats [7]. 
Part of this research has been presented at the 15th 
Congress of the European Society of Parenteral and En- 
teral Nutrition (1993). 
2. Materials and methods 
not eat all food offered at once and would subsequently be 
starved for the remainder of the day. Measurements were 
performed 16 h and 2, 4, and 6 days after treatment. Also a 
control group with free access to the rat chow and no 
paraffin injections was included in the study. All groups 
were matched for age and initial body weight. During the 
experiment food intake and body weight were determined 
daily. 
On the day of the measurements pair feeding was 
performed at 07.00 h and food was withheld from 08.00 h 
till 12.00 h. Sampling of muscle tissue was done between 
12.00 h and 14.00 h. Animals were killed by cervical 
dislocation and the gastrocnemius muscle was rapidly re- 
moved, weighed, freeze-clamped in liquid nitrogen and 
stored at -80°C until analysis. 
For metabolite determination muscle was homogenized 
in ice-cold 1 M perchloric acid (1:5) with an OMNI 1000 
mechanical homogenizer. The supernatant was neutralized 
with 2 M potassium bicarbonate and used for measuring 
muscle metabolites: 
1. ATP, ADP, AMP, creatine phosphate, creatine, pyru- 
vate and lactate were measured as described by Harris 
and colleagues [10]. 
2. Citrate, malate and succinate were measured as de- 
scribed in Methods of Enzymatic Analysis [l 1-13]. 
All these analyses were modified for measurement on a 
spectrophotometric centrifugal analyzer (COBAS-BIO, 
Roche Diagnostica). 
A small part (10-60 rag) of the frozen muscle was used 
to determine glycogen content. Free glucose was separated 
from glycogen by dissolving muscle in 1 M NaOH (37°C, 
Male SPF Lewis rats were supplied by the animal house 
of the University of Limburg. They were individually 
housed and kept in a controlled environment (12 h light 
cycle, 21-22°C and 50-60% humidity). Rats were fed a 
standard lab chow (SRM-A, Hope Farms, The Nether- 
lands) containing (wt/wt) approx. 28% protein, 7% fat, 
54% carbohydrates, 4% fibers and 7% minerals with a 
trace element and vitamin supplement. Rats were allowed 
to acclimatize to individual housing for one week. All 
experiments were approved by the Animal Experimental 
Committee of the University of Limburg. 
Recently we have reported concentrations of amino 
acids and protein synthesis rates in zymosan-treated rats 
[7]. The same rats were used for the measurements de- 
scribed in the present paper. 
Critical illness was induced by intraperitoneal injection 
of zymosan (50 mg per 100 g body weight) suspended in 
sterile liquid paraffin (25 mg/ml) as described before [7]. 
Food intake was substantially reduced after zymosan ad- 
ministration and, therefore, paraffin-injected control rats 
were pair-fed. Pair feeding was performed in three periods 
during the day (from 08.00 h till 15.00 h, 15.00 h till 22.00 
h, and from 22.00 h till 08.00 h). This was done to ensure 
that the pair-fed rats had a similar eating pattern and would 
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Fig. 1. Concentrations of ATP measured in muscle 16 hours (h) and 2, 4, 
and 6 days (d) after treatment. Values are given as mean (range) of 6 -8  
rats. The gray area represents the range of the ad libitum-fed control rats. 
* Significantly different from ad libitnm and #pair-fed control rats. 
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Table 1 
Concentrations of adenine nucleotides ( #mol/g wet weight) 
treatment 
and the energy charge measured in muscle 16 hours (h) and 2, 4 and 6 days (d) after 
ADP AMP AMP + ADP + ATP Energy charge 
con 0.9 (0.82-0.99) 0.047 (0.041-0.052) 8.8 (7.3-10.4) 0.942 (0.927-0.952) 
16 h zym 0.9 (0.82-0.90) ~ 0.073 (0.066-0.096) " 7.6 (7.3-8. I ) " 0.934 (0.928-0.938) ~ 
pf 0.9 (0.84-0.95) 0.074 (0,064-0.090) " 7.7 (7.3-8.0) " 0.933 (0.930-0.935) ~'
2 d zym 1.0 (0.88-1.02) 0.057 (0.052-0.060) ~ 8.7 (7.7-9.5) 0.939 (0.935-0.945) h 
pf 0.9 (0.76-1.12) 0.053 (0.041-0.060) " 9.2 (7.7-II. 1) 0.945 (0.938-0.952) 
4 d zym 0.8 (0.65-0.94) 0.054 (0.045-0.066) ~ 7.4 (5.4-9. I ) " 0.935 (0.923-1).943) 
pf 0.9 (0.71 - 1.05) 0.056 (0.041-0.075) 8.6 (7,8-9.1) 0.940 (0.930-0.948) 
6 d zym 0.9 (0.85-0.97) 0.050 (0.044-0.057) 7.6 (7.3-8.0) ~' 0.934 (0.932-0.936) ~'
pf 0.9 (0.86-0.98) 0.047 (0.043-0.050) 8.5 (6.8-10.3) 0.940 (0.926-0.951 ) 
Energy charge ,,,,'as calculated as [ATP + 0.5ATP]/[ATP + ADP + AMP]. Values are given as mean (range) of 6-8 rats. 
Con. ad libitum-fed control; zym, zymosan-treated; pf. pair-fed rats. 
a Significantly different from control: h significantly different from pair-fed. 
I h) and precipitat ing lycogen with 96% ethanol  (80°C 
for 10 rain and then overn ight  at 4°C). The g lycogen pel let 
was hydro lyzed using 1 M HCI (100°C, 3 h). HCI was 
neutral ized with a KCI saturated KOH/Yr i s  (2.1 M/0 .12  
M) buffer. Glucosyl  units obta ined from glycogen were 
determined using a g lucose kit (Hexok inase method,  
Roche)  for a centr i fugal  analyzer  (COBAS-B IO,  Roche 
Diagnost ica).  
Di f ferences between pair- fed and zymosan-t reated rats 
and between zymosan-t reated and ad l ib i tum-fed control  
rats were analyzed for statistical s igni f icance using the 
Mann-Whi tney  U-test. S igni f icance was set at P < 0.05. 
All measurements  were done in duplicate. Values are 
g iven as mean (range). 
3. Resul ts  
Rats injected with zymosan showed both cl inical 
( lethargy, anorexia,  d iarrhea) and metabol ic  (muscle wast- 
Table 2 
Concentrations of creatine and total creatine pool (/xmol/g wet weight) 
measured in muscle 16 hours (h) and 2, 4 and 6 days (d) after treatment 
Creatine Creatine + creatine 
phosphate 
con 17.5 (15.7-20.5) 35.4 (33.8-37.9) 
16h zym 17.4 (15.8-19.1) 31.9(30.5-33.2) ~ 
pf 16.8 (9.3-21.0) 31.1 (23.4-35.3) ~ 
2 d zym 19.4 (14.7-22.8) 35.0 (26.6-38.8) 
pf 18.0 (16.2-20.1 ) 33.5 (20.1-39.0) 
4 d zym 18.8 (14.6-21.1) h 34.8 (27.7--37.4) 
pf 21.3 (19.9--24.1) ~' 37.6 (34.3--39.9) ~ 
6 d zym 17.7 (15.9-18.9) 36.0 (32.8-38.6) 
pf 18.2 (16.2-19.9) 35.8 (32.4-37.2) 
Values are given as mean (range) of 6-8 rats. 
Con, ad libitum-fed control; zym, zymosan-treated; pf, pair-fed rats. 
~' Significantly different from control; b significantly different from pair- 
fed. 
ing, decreased g lutamine pools and enlarged l iver) signs of 
critical i l lness [7]. A mortal i ty rate of  16% was observed in 
this study. All deaths occurred dur ing the first 36 h. 
Pair- fed and ad l ib i tum-fed control rats showed none of  
these signs. Detai ls of  the animal model  including changes 
in food intake, body weight  and protein synthesis rates 
have been descr ibed e lsewhere [7]. 
3.1. Concentrations of  adenine nucleotides (Table 1) 
Concentrat ions of ATP  (Fig, l), the sum of  ATP,  ADP 
and AMP and the energy charge were decreased in both 
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Fig. 2. Concentrations of creatine phosphate measured in muscle 16 hours 
(h) and 2, 4, and 6 days (d) after treatment. Values are given as mean 
(range) of 6-8 rats. The gray area represents the range of the ad 
libitum-fed control rats. *Significantly different from ad libitum and 
#pair-fed control rats. 
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pair-fed and zymosan-treated rats in comparison with ad 
libitum-fed control rats 16 h after treatment. AMP concen- 
trations were increased in both experimental groups after 
16h. 
Concentrations of ATP (Fig. 1) were decreased in mus- 
cle of zymosan-treated rats on day 4 in comparison with 
both control groups and on day 6 in comparison with ad 
libitum-fed control rats. The sum of ATP, ADP and AMP 
was decreased on days 4 and 6 in comparison with ad 
libitum-fed control rats. The energy charge was marginally 
decreased in muscle of zymosan-treated rats on day 2 in 
comparison with the pair-fed controls and on day 6 in 
comparison with the ad libitum-fed control rats. 
3.2. Concentrations of creatine and creatine phosphate 
(Table 2) 
Table 3 
Concentrations ( mol/g wet weight) of tricarboxylic a id cycle interme- 
diates (citrate, succinate and malate) measured in muscle 16 hours (h) and 
2, 4 and 6 days (d) after treatment 
Citrate Succinate Malate 
con 169 (142-198) 270 (213-321) 307 (266-347) 
16 h zym 167 (134-228) 391 (335-495) a 338 (285-422) ~ 
pf 173 (149-204) 372 (327-430) ~ 292 (224-345) 
2 d zym 124 (92-155) a 285 (201-390) 356 (237-480) b
pf 149 (116-191) 286 (176-406) 292 (225-369) 
4 d zym 100 (50-147) a 248 (141-348) 255 (181-343) 
pf 102 (73-121) ~ 258 (195-334) 262 (221-320) ~
6 d zym 150 (92-204) 207 (156-274) a 222 (204-260) ~.b 
pf 135 (108-164) a 284 (197-420) 314 (253-410) 
Values are given as mean (range) of 6-8 rats. 
Con, ad libitum-fed control; zym, zymosan-treated; pf, pair-fed rats. 
a Significantly different from control; ~ significantly different from pair- 
fed. 
Concentrations of creatine phosphate (Fig. 2) and the 
total creatine pool (sum of creatine and creatine phosphate) 
were decreased 16 h after treatment in pair-fed and zy- 
mosan-injected rats in comparison with ad libitum-fed 
control rats. 
Concentrations of creatine were decreased in muscle of 
zymosan-treated rats on day 4 in comparison with pair-fed 
control rats. However, creatine concentrations in pair-fed 
control rats were increased on this day in comparison with 
ad libitum-fed rats. Concentrations of creatine phosphate 
(Fig. 2) were decreased 2 days after zymosan treatment in 
comparison with both ad libitum- and pair-fed control 
groups. 
3.3. Concentrations of tricarboxylic acid cycle intermedi- 
ates (Table 3) 
Of the TCA cycle intermediates citrate, succinate and 
malate were measured, The sum of these intermediates 
represents about 70% of the total TCA cycle intermediate 
pool [14] and, therefore, this value is considered as a good 
indication of changes in the level of the total TCA-cycle 
intermediate pool in muscle. 
Sixteen h after treatment both succinate concentrations 
and the sum of TCA intermediates (Fig. 3) were increased 
in zymosan-treated and pair-fed rats in comparison with ad 
libitum-fed control rats. 
Concentrations of citrate were decreased in zymosan- 
treated rats on day 2 in comparison with ad libitum-fed 
control rats. Succinate concentrations were decreased 6
days after zymosan treatment in comparison with ad libi- 
turn-fed control rats, Concentrations of malate were in- 
creased after 16 h and 2 days in comparison with pair-fed 
controls and decreased on 6 days after zymosan treatment 
in comparison with both ad libitum- and pair-fed animals. 
The sum of citrate, succinate and malate (Fig. 3) was 
decreased on day 6 in comparison with both control groups. 
3.4. Concentrations of pyruuate, lactate and glycogen 
(Table 4) 
Concentrations of both lactate and glycogen were de- 
creased in muscle of zymosan-treated and pair-fed rats in 
Table 4 
Concentrations pyruvate (nmol/g wet weight), lactate (/zmol/g 
hours (h) and 2, 4 and 6 days (d) after treatment 
wet weight) and glycogen (/zmol glucosyl units/g wet weight) measured in muscle 16 
Pyruvate Lactate Lact/pyr Glycogen 
con 84 (75-100) 4.1 (2.8-5.6) 46 (34-67) 162 (149-181) 
16 h zym 68 (62-84) ~ 2.6 (1.9-3.4) ~ 38 (28-46) 132 (96-154) a 
pf 70 (52-81) 2.8 (2.1-4.0) a 40 (25-59) 130 (114-154) a
2 d zym 88 (63-111) 2.8 (1.3-4.0) 31 (19-43) a 123 (112-138) a
pf 86 (76-99) 3.6 (2.5-5.0) 43 (29-60) 154 (97-202) 
4 d zym 72 (53-97) 3.0 (1.7-4.8) b 40 (32-54) 160 (103-214) 
pf 93 (63-114) 4.9 (3,3-6.9) 57 (34-11 l) 181 (159-214) 
6 d zym 65 (58-69) a.b 3.0 (2.1--3.8) 46 (31--65) 214 (193-248) a
pf 84 (78--93) 4. l (3.0--5.7) 49 (36--73) 206 (185--230) a 
Values are given as mean (range) of 6-8 rats. 
Con, ad libitum-fed control; zym, zymosan-treated; pf, pair-fed rats. 
a Significantly different from control; bsignificantly different from pair-fed. 
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Fig. 3. Concentrations of TCA cycle intermediates (sum of citrate succi- 
nate and malate) measured in muscle 16 hours (h) and 2, 4, and 6 days 
(d) after treatment. Values are given as mean (range) of 6-8 rats. The 
gray area represents he range of the ad libitum-fed control rats. * Signifi- 
candy different from ad libitum and #pair-fed control rats. 
comparison with ad libitum-fed control rats 16 h after 
treatment. Glycogen concentrations were increased in both 
experimental groups on day 6 in comparison with ad 
libitum-fed control rats. 
Concentrations of pyruvate were decreased in muscle 
16 h after zymosan treatment in comparison with ad 
libitum-fed control rats and on day 6 in comparison with 
both ad libitum- and pair-fed control rats. On day 2 the 
lactate/pyruvate ratio and the glycogen concentration were 
decreased in the zymosan-treated rats in comparison with 
ad libitum-fed control rats. 
4. Discussion 
In skeletal muscle of both zymosan-treated and pair-fed 
rats comparable decreases in concentrations of ATP and 
creatine phosphate, and increases in concentrations of AMP 
and succinate were observed 16 h after treatment. This 
indicates that the zymosan-induced changes in muscle 
energy metabolism during the early phase of acute critical 
illness are mainly the result of a decreased food intake. 
The abnormalities present in the pair-fed group tended to 
normalize after 16 h. During the prolonged recovery period 
most changes are the result of the zymosan treatment 
independent of the food intake. The substantial influence 
of the reduced food intake early after the insult indicates 
that food intake should be carefully controlled in this kind 
of metabolic studies. 
Concentrations of high energy phosphates were de- 
creased in muscle of zymosan-treated rats to a moderate 
extent only. Concentrations of creatine phosphate were 
reduced to 87% of control 2 days after injection. ATP 
levels were 83 and 85% of the ad libitum-fed control 
values on day 4 and 6 respectively. In muscle of both 
patients and animal models dramatic hanges in adenine 
nucleotides have only been observed uring critical illness 
with fairly high mortality rates. Decreased ATP concentra- 
tions of approx. 50% have been measured in critically ill 
patients with mortality rates over 80% [2,3]. In a study of 
Liaw and colleagues [1] substantial decreases in concentra- 
tions of ATP, ADP and creatine phosphate were only 
observed in the critically ill patients and not in moderately 
and severely ill patients. Rats with severe burn trauma 
showed a large (62%) decrease in muscle concentrations of 
ATP [5]. Other animal models with less severe illness or 
trauma showed no changes [15-17] or small changes [4,6] 
in concentrations of adenine nucleotides. 
A reduction in TCA cycle intermediates was measured 
on day 6 after zymosan treatment only, whereas the reduc- 
tion of mitochondrial content was observed over a longer 
period [8]. In addition, the decrease in mitochondrial con- 
tent seems to be larger than that of the TCA cycle interme- 
diates. These result indicate that the concentration of TCA 
cycle intermediates per mg of mitochondrial protein is 
increased. The changes in TCA cycle intermediates were 
in general not paralleled by changes in high energy phos- 
phates and, therefore, do not appear to induce a derange- 
ment in the energy metabolism under the circumstances 
studied. The decreased concentration of TCA cycle inter- 
mediates may, however, reduce the availability of carbon 
skeletons for the production of glutamine via 2-oxogluta- 
rate and glutamate [9]. Glutamine has been suggested to 
become a conditionally essential amino acid for the criti- 
cally ill because the body's requirements for glutamine 
seems to exceed the ability to produce glutamine [18]. 
Decreased muscle and plasma concentrations of glutamine 
are commonly observed in critically ill patients and animal 
models, including the zymosan-treated rats [7]. 
No substantial differences in glycogen and lactate con- 
centrations were observed between the groups. Decreased 
glycogen concentrations and increased lactate concentra- 
tions are expected when the anaerobic production of ATP 
via the glycolysis and glycogenolysis i  increased. The 
lactate/pyruvate ratio was not changed in muscle of zy- 
mosan-treated rats. This indicates that maintenance of the 
NADH/NAD ratio by the oxidative phosphorylation was 
not impaired. In addition, maintenance of the NADH/NAD 
ratio implies that the oxygen supply is not limited. This 
rules out the possible occurrence of anoxia in this model. 
These results indicate that, in spite of the decreased mito- 
chondrial content, the oxidative capacity is adequate to 
meet the cellular energy needs in skeletal muscle of zy- 
mosan-treated rats at rest. 
Although the results indicate that the oxidative capacity 
of the muscle is not limited, decreased concentrations of
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ATP were observed on days 4 and 6 after zymosan treat- 
ment. These changes are, however, not accompanied or 
preceded by decreased concentrations of creatine phos- 
phate. Normally an energy deficit will lead to a substantial 
decrease of the concentration of creatine phosphate before 
ATP levels start to drop. This supports the conclusion that 
no derangement in the muscle energy metabolism is pre- 
sent. Most likely, the decrease in ATP is the result of a 
general oss of adenine nucleotides either by a decreased 
production or increased breakdown. The same phe- 
nomenon has been observed in both severely ill patients 
[3,19] and animals [6]. 
Decreased activities of citrate synthase and cytochrome- 
c oxidase were previously observed in muscle of 
zymosan-treated rats up to 6 days after treatment [8]. This 
indicates that the mitochondrial content is reduced. In a 
study of Dudley and colleagues [20] muscle energy 
metabolism has been studied in rats with different mito- 
chondrial contents in skeletal muscle. Only minor differ- 
ences were observed in muscle ATP and creatine phos- 
phate/creatine concentrations at rest. However, in situ 
electrical stimulation resulted in large decreases in high 
energy phosphates in the low mitochondria group and 
small decreases in the high mitochondria group. Also in 
muscle of tumor-bearing rats decreased concentrations of
ATP were only observed in the soleus muscle after in situ 
stimulation and not in the resting state [21]. This indicates 
that also in muscle of zymosan-treated rats the oxidative 
capacity may be sufficient o prevent dramatic decreases in
concentrations of high energy phosphates at rest but not 
during an increased contractile activity. 
Protein synthesis rates have also been measured in 
muscle of the same rats as used in the present study [7]. 
Only at 16 h after treatment protein synthesis rates were 
decreased. No decreases in concentrations of high energy 
phosphates were observed at this time point, which seems 
to suggest hat a reduced availability of energy substrates 
is not the cause of the reduced protein synthesis rates. 
In conclusion, modest decreases in concentrations of 
high energy phosphates have been observed in resting 
skeletal muscle of zymosan-treated rats both during the 
acute phase of critical illness and during recovery. These 
decreases were, however, not accompanied by a derange- 
ment in the TCA cycle or by an increased anaerobic 
production of ATP. We, therefore, conclude that, although 
the maximal oxidative capacity (mitochondrial content) is 
decreased in skeletal muscle of zymosan-treated rats, no 
derangement in energy metabolism seems to be present at 
rest. The decreased concentration of TCA cycle intermedi- 
ates observed in skeletal muscle during recovery may have 
consequences for the glutamine production. Because of the 
putative clinical importance of glutamine during severe 
illness this aspect should be investigated in greater detail. 
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